Attached files

file filename
10-K - FORM 10-K - Vaxart, Inc.d10k.htm
EX-23 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Vaxart, Inc.dex23.htm
EX-31.1 - RULE 13A-14(A)/ 15D-14(A) CERTIFICATION - Vaxart, Inc.dex311.htm

EXHIBIT 32

Nabi Biopharmaceuticals

SECTION 1350 CERTIFICATION

The undersigned officer of Nabi Biopharmaceuticals (the “Company”) hereby certifies that, as of the date of this statement, the Company’s report on Form 10-K for the year ended December 26, 2009 (the “Report”) fully complies with the requirements of section 13(a) of the Securities Exchange Act of 1934 and that, to the best of his knowledge, information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of December 26, 2009 and the results of operations of the Company for the year ended December 26, 2009.

The purpose of this statement is solely to comply with Title 18, Chapter 63, Section 1350 of the United States Code, as amended by Section 906 of the Sarbanes-Oxley Act of 2002. This statement is not “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Act or any other federal or state law or regulation.

 

Date: March 10, 2010    

/S/    RAAFAT E.F. FAHIM, PH.D.        

  Name:   Raafat E.F. Fahim, Ph.D.
  Title:   Chief Executive Officer, President and Acting Chief Financial Officer